Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • a day ago

Cancer Stock Breaks Out To Highs; Key FDA Action On Watch

Cancer treatment name Exelixis is attempting to clear a flat base with a 57.57 pivot.

Investors Business Daily • Sep 2, 2026

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Wells Fargo 21st Annual Healthcare Conference: Exelixis is scheduled to present at 11:00 a.m. ET / 8:00 a.m. PT on Tuesday, September 8 in Boston. Citi 2026 Biopharma Back to School Conference: Exelixis is scheduled to present at 8:40 a.m. ET / 5:40 a.m. PT on Wednesday, September 9 in New York City. Morgan.

Business Wire • Sep 1, 2026

Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data

Exelixis is downgraded from "Strong Buy" to "Hold" due to lowered 2026 revenue guidance and mixed clinical trial outcomes. Zanzalintinib + TECENTRIQ achieved overall survival benefit in mCRC, but missed the non-liver metastases subgroup endpoint; FDA PDUFA date set for December 3, 2026. Q2 2026 revenues rose to $628.7M, but future sales growth is uncertain and full-year guidance was cut to $2.500–$2.550B.

Seeking Alpha • Sep 1, 2026

Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. Court of Appeals for the Federal Circuit (Appeal No. 25-1236) has affirmed a key portion of the 2024 judgment of the U.S. District Court for the District of Delaware in Exelixis' favor. The appellate court upheld the District Court's decision that three patents covering.

Business Wire • Aug 31, 2026

Strong Sales, Earnings Send Exelixis Shares Higher

Exelixis, Inc. (EXEL) shares enjoying institutional support – up 43.5% in a year.

FXEmpire • Aug 28, 2026

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Aug 20, 2026

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. ( NASDAQ : EXEL) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

PRNewsWire • Aug 19, 2026

Here's Why Exelixis (EXEL) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Aug 18, 2026

Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky

Exelixis posted second-quarter revenue of approximately $628.7 million -- short of Wall Street consensus -- and shares sold off in after-hours trading. Levi & Korsinsky is investigating.

PRNewsWire • Aug 17, 2026